Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

Abstract: Provided is a method and a composition for breaking dormancy in deciduous trees.

Abstract: A system having an elongated body defining a hollow passageway therethrough, which includes as a first opening disposed about a longitudinal upper half of the elongated body, and at least two second openings disposed about longitudinal side zones of the elongated body, wherein each of the at least two second opening has an area of between 80 and 700 cm2.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Abstract: Methods and systems for providing distributed tracing for application performance monitoring utilizing a distributed search engine in a microservices architecture. An example method comprises providing a user interface (UI) including a distributed trace indicating in real time the services invoked to serve an incoming HTTP request, the UI further including, in a single view, associated execution times for the services shown as a timeline waterfall. The distributed trace automatically propagates a trace ID to link services end-to-end in real time until a response to the request is served. The single view also provides graphs of response time information and the distribution of response times for the services. In response to selection of a particular element of the distribution, the UI provides respective timing details. The graphs and data shown on the single view can be filtered based on metadata input into a search field of the single view.

Abstract: Methods and corresponding systems for integration of different data for a distributed search, visualization and analysis platform, the method comprising automatically correlating data sources associated with execution of an application, the data from the data sources adhering to a common schema. The method further comprises providing a separate UI for each of the data sources for visualization and analysis; for each UI, providing a menu for selecting other correlated data sources; and in response to a menu selection, causing display of the other correlated data source and its corresponding UI. The data sources may include application performance monitoring (APM) data, log data, and infrastructure data. The common schema provides a core set of fields to be used in event messages stored for APM data, log data, and infrastructure data, and is configured to enable adding new data sources while enabling reuse of existing analysis content for the new data sources.

Abstract: Methods and corresponding systems for integration of different data for a distributed search, visualization and analysis platform, the method comprising automatically correlating data sources associated with execution of an application, the data from the data sources adhering to a common schema. The method further comprises providing a separate UI for each of the data sources for visualization and analysis; for each UI, providing a menu for selecting other correlated data sources; and in response to a menu selection, causing display of the other correlated data source and its corresponding UI. The data sources may include application performance monitoring (APM) data, log data, and infrastructure data. The common schema provides a core set of fields to be used in event messages stored for APM data, log data, and infrastructure data, and is configured to enable adding new data sources while enabling reuse of existing analysis content for the new data sources.

Abstract: Methods and systems for providing integration of log, infrastructure, and application performance monitoring (APM) data sources for visualization and analysis. An example method includes automatically correlating data sources associated with execution of an application, the data sources associated with the execution including log data from services invoked, infrastructure data, along with application performance monitoring (APM) trace information that indicates in real time at least execution time information for the services; providing a separate user interface (UI) for the each correlated data source for visualization and data analysis; and in response to a selection by a user at one of the separate UIs, causing display of one of the other correlated data sources at another of the separate UIs. The method streamlines debugging. One of the UIs provides for selection of infrastructure metrics for display where example infrastructure includes a plurality of container and hosts.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

Abstract: Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

Abstract: A composite characterized by an average density of 60 Kg/m3 to 180 Kg/m3, with at least two portions having a different density of at least 20 Kg/m3, made of a binder, and a foamed elastomer or a foamed rigid polymer, is disclosed herein. Uses of the composite and of matrices and articles incorporating same for the improvement of plant growing and/or weed control are further disclosed.

Abstract: Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.

Abstract: A nonvolatile memory system, a nonvolatile memory controller and a method for reducing latency of a memory controller are disclosed. The nonvolatile memory system includes a read circuit that performs background reads of an indicator page of each block to identify outlier blocks. A background reference positioning circuit performs background reads of representative pages of the outlier block at threshold voltage offsets to identify sets of updated threshold voltage offset values. Upon endurance events, retention timer events and read disturb events at a closed block background reads are performed of representative pages of the closed block at threshold voltage offsets to identify sets of updated threshold voltage offset values.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Abstract: Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.

Abstract: A process for determining responders in clinical testing environments that involves, inter alia, detecting treatment response through the use of small numbers of measurements of randomly varying outcome variables in individual clinical trial subjects, and by analyzing the measurements in such a way as to eliminate troublesome variables, such as a spontaneous population variability.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.